截至2025年6月，植物医生在全球已开设4269家线下门店，如今门店覆盖中国、日本、印尼、泰国等多 个市场。这一密集的零售网络不仅为公司带来稳健的营收基础，更通过面对面服务增强了用户黏性与品 牌体验。公司已连续多年位列中国单品牌化妆品店零售额榜首，线下渠道优势显著。植物医生不仅输出 产品，更通过本土化运营传递"高山植物"的东方护肤哲学，其"全球领先的单品牌护肤品专卖店"认证也 进一步强化了国际市场的专业形象。 截至2025年10月，植物医生已累计获得223项专利，其中发明专利68项，并完成了齿瓣石斛茎提取物等 新原料备案。这种"研发-专利-原料-产品"的闭环能力，使公司能够持续将高山植物资源转化为具有市场 竞争力的护肤成分，不断强化"中国成分"的科技内涵。 前不久，深圳证券交易所官网更新了植物医生（DR PLANT）的IPO项目动态，正式向A股主板发起冲 刺，标志着企业资本化进程的关键一步。 植物医生自创立以来，始终聚焦"高山植物，纯净美肌"的战略定位，围绕"中国品牌、中国成分"打造差 异化优势。这一清晰定位使其在竞争激烈的化妆品市场中形成了鲜明的品牌辨识度，为持续增长奠定了 品牌基础。 品牌的核心竞争力建立 ...

Core Viewpoint - The IPO progress of DR PLANT has garnered significant attention, showcasing a unique development path in the cosmetics industry that emphasizes offline network cultivation and a solid research framework for sustainable brand growth [1] Group 1: Offline Network and Brand Interaction - DR PLANT has established a robust offline store network, with 4,269 stores projected by June 2025, extending beyond China to countries like Japan, Thailand, and Indonesia [3] - The stores serve not just as sales points but as service spaces that enhance product experience and emotional connection, fostering genuine interaction and trust between consumers and the brand [3] - The "product + service + scenario" offline model has led to stable performance, positioning the brand among the top 100 chain enterprises in the lifestyle service industry for two consecutive years, and aiming to become the top single-brand cosmetics retailer in China by 2024 [3] Group 2: Research and Development Focus - Unlike many brands that rely on outsourcing and marketing, DR PLANT has invested in a systematic research and development framework centered around "highland plants and pure beauty" since its inception [3] - The establishment of the "Chinese Academy of Sciences Kunming Plant Research Institute R&D Center" and five research bases in various locations ensures a deep integration of production, learning, and research, enabling the continuous launch of differentiated products backed by technology [3][4] - A notable example of R&D success is the innovation in the use of Dendrobium polysaccharides, transforming them into more absorbable oligosaccharides, leading to the popular Dendrobium product line, which has won national awards and enhanced the brand's standing in the cosmetics efficacy domain [4] Group 3: Brand Narrative and Cultural Integration - The brand narrative intertwines traditional wisdom from the Naxi culture with modern scientific principles, creating a unique cognitive asset that resonates with consumers [4] - This cultural and scientific integration has facilitated the brand's international expansion, allowing it to convey the cultural essence of Eastern plant skincare while achieving recognition as a leading single-brand skincare store globally for three consecutive years [4] - By 2025, the brand's global store count is expected to exceed 4,200, serving over 30 million members, demonstrating its capability for systematic cross-regional expansion [4] Group 4: Strategic Logic and Future Outlook - The focus of DR PLANT's IPO is not merely on growth figures but on a clear strategic logic that emphasizes solid channel operations and ongoing research innovation to build a competitive advantage that is hard to replicate [5] - Support from the capital market may enhance R&D, optimize supply chains, and accelerate internationalization, highlighting the potential for a different approach in a market characterized by flow anxiety [6] - The brand's growth is rooted in a commitment to its core values and a deep focus on delivering value, suggesting a path that may be slower but is more stable and sustainable in the long run [6]

Core Insights - The company, Plant Doctor, is accelerating its IPO amidst intensifying competition in the Chinese cosmetics industry, focusing on high-altitude plant skincare as its niche market [1] - The brand's positioning of "high-altitude plants, pure beauty" aligns with consumer demand for natural, safe, and effective skincare ingredients, establishing a unique competitive advantage [1] Financial Performance - From 2021 to the first half of 2024, the company's revenue has consistently exceeded 2.1 billion yuan, with net profit increasing from 158 million yuan to 243 million yuan in 2023, reflecting a compound annual growth rate of 24% from 2022 to 2024 [2] - The net profit scale significantly surpasses the median level of industry peers, indicating strong profitability and industry representation [2] Channel Strategy - The company has developed a multi-channel strategy, with a focus on offline single-brand stores and an extensive online presence, achieving 4,269 offline stores by June 2025 [2] - The offline network not only generates substantial sales revenue but also serves as a brand image showcase and customer experience center, enhancing customer loyalty [2] Online Growth - Online channels act as a growth engine, with deep operations on platforms like Tmall and Douyin, and the introduction of the "Little Plant City" new retail model, which effectively channels offline traffic to online private domains [3] - This integration of online and offline sales has positioned the company as the top single-brand cosmetics store in China [3] R&D Investment - The company has invested nearly 250 million yuan in R&D during the reporting period, establishing a comprehensive research framework that includes basic plant research, formula development, and clinical testing across multiple locations [3] - As of October 2025, the company has secured 223 patents, ensuring continuous product innovation and rapid market responsiveness [3] Future Strategy - The IPO proceeds will be allocated to brand marketing, upgrading the R&D center, technological transformation of production bases, and information system development, outlining a clear strategic path for future growth [3] - By leveraging its focus on high-altitude plants, ongoing R&D, differentiated channel strategies, and clear brand positioning, the company aims to establish a competitive moat in the skincare market [3]

Core Insights - The domestic high-altitude plant skincare brand DR PLANT is updating its IPO process and plans to list on the Shenzhen Stock Exchange main board, supported by over 4,200 offline stores and a focus on "high-altitude plants" to differentiate itself in a homogenized market [1] R&D and Innovation - The company's prospectus emphasizes its R&D structure and technological achievements, indicating that its core competitive advantage lies in systematic research capabilities [3] - A unique asset is the deep collaboration with the Kunming Institute of Botany, Chinese Academy of Sciences, leading to the establishment of the Zhongke Kunzh plant doctor R&D center, which serves as the "brain" for product innovation [3] - The company has established five R&D bases across Beijing, Guangdong, Yunnan, Jiangsu, and Tokyo, creating a global R&D network covering fundamental research, raw material development, formulation processes, clinical testing, and Eastern skincare science [3] - As of October 2025, the company has obtained 223 patents, including 68 invention patents, establishing a solid intellectual property moat [3] - A notable achievement is the deep development of "Dendrobium," where patented technology converts large molecular Dendrobium polysaccharides into more absorbable Dendrobium oligosaccharides, proving effective in promoting collagen regeneration in the skin [3] Market Strategy and Channel Development - The company has chosen a "heavier" but more stable channel strategy, with 4,269 global single-brand chain stores and over 30 million members as of June 2025, recognized for two consecutive years by Euromonitor as a "global leader in single-brand skincare specialty stores" [4] - Stores serve not only as sales terminals but also as brand experience centers offering professional care and member salons, creating unique emotional value and user stickiness, transforming one-time purchases into long-term membership relationships [4] - The extensive offline network provides a predictable revenue base, mitigating risks from online traffic fluctuations, while millions of members form a rich private traffic pool for product iteration and precise marketing [4] - The capital journey coincides with a critical shift in the domestic cosmetics industry from internal competition to external value expansion, with a successful IPO expected to open a new development phase for the company [4] - The challenge lies in leveraging capital advantages to accelerate expansion while maintaining brand tone and operational quality, with the balance between scale and efficiency being crucial for establishing a strong global presence [4]

Core Viewpoint - The company, Plant Doctor, has officially initiated its IPO process for listing on the A-share main board, focusing on high-altitude plant skincare products and emphasizing its brand strategy of "high-altitude plants, pure beauty" [1] Group 1: R&D and Product Development - Plant Doctor has established a deep collaboration with the Kunming Institute of Botany, forming the "Plant Doctor R&D Center," which includes a unique research structure of "one center and five bases" [3] - The R&D framework covers raw material research, formula development, production processes, and quality assurance, with significant breakthroughs in the field of Dendrobium orchid active ingredients [3] - The company has developed a product matrix that includes various series such as "Dendrobium Orchid Firming and Smoothing" and "Snow Lotus Soothing Care," covering multiple product categories [5] Group 2: Business Model and Market Position - Plant Doctor employs an online and offline strategy, with over 4,200 offline chain stores by June 2025, providing unique product experiences and emotional value to consumers [7] - According to a report by the China Fragrance and Cosmetic Industry Association, Plant Doctor ranks first among single-brand cosmetic stores in China based on projected retail sales for 2024 [7] Group 3: International Expansion and Recognition - The company has made substantial progress in its international strategy, with store networks covering multiple countries, including Thailand, where it opened a flagship store in November 2025 [7] - Plant Doctor has been recognized as a "global leading single-brand skincare specialty store" by Euromonitor International for three consecutive years, reflecting its strong market position [9] Group 4: Brand Philosophy and Future Outlook - The brand philosophy is rooted in traditional Chinese culture, integrating the wisdom of Naxi herbal medicine with modern biotechnology, aiming to provide consumers with a pure skincare experience from high-altitude plants [9] - With the advancement of its IPO process, Plant Doctor is expected to leverage capital market resources to strengthen its leading position in high-altitude plant skincare and accelerate its international expansion [9]

Core Insights - The long-term vitality of the brand is rooted in differentiated core competitiveness, emphasizing the need to build unique value barriers to cultivate a trust-based consumer group [1] - DR PLANT, a brand focused on high-altitude plant skincare, is set to launch an IPO on the Shenzhen Stock Exchange, driven by its brand strategy of "high-altitude plants, pure beauty" and systematic research capabilities [1] Research and Development - The foundation of the brand's competitiveness lies in its deep commitment to research, having established the "Chinese Academy of Sciences Kunming Plant Research Institute R&D Center" in 2014 to conduct systematic studies on high-altitude plant skincare [3] - High-altitude plants possess strong resistance and higher active substance content compared to ordinary plants, aligning with modern consumer demands for "pure beauty" [3] - The brand combines traditional Chinese herbal essence with modern technology, achieving global recognition with products like Dendrobium and Qingci fruit, and has been certified as the "global leader in Dendrobium skincare retail sales" by Euromonitor [3] R&D Infrastructure - The research system has evolved into a "1 center + 5 bases" structure, covering the entire chain from basic research to industrial application [4] - The Tokyo R&D center, established in 2016, serves as an "international bridge," integrating advanced extraction technologies from Japan with Chinese high-altitude plant resources to develop customized products for overseas markets [4] - As of October 31, 2025, this system has generated 223 patents, with the "Key Technology Research and Industrial Application of Dendrobium Active Extract" project winning a national award for commercial technological progress, showcasing industry-leading capabilities [4] Market Channels - The brand has established a unique "experience + sales + service" model through a dense network of 4,269 offline stores, enhancing the synergy between research, products, and channels [6] - The brand has received recognition as the "number one single-brand cosmetics store in China" and has gained loyal users in overseas markets such as Japan and Indonesia [6] IPO and Future Plans - The IPO aims to raise funds, with 260 million yuan earmarked for upgrading the R&D center to further strengthen technological barriers [7] - The brand views the IPO as a new starting point to continuously activate its research potential and deepen its global layout in the single-brand store sector [9] - This research-driven development path injects substantial growth momentum into the brand and propels domestic beauty products from price competition to value competition [9]

Core Viewpoint - The IPO of Plant Doctor, a company focused on high-altitude plant skincare and a single-brand chain model, reflects a significant shift in the Chinese cosmetics industry towards brand value and sustainable business models after a period of intense competition and marketing frenzy [1] Group 1: Company Overview - Plant Doctor has over 30 years of experience and integrates traditional wisdom from the Naxi culture into its modern brand strategy, emphasizing "high-altitude plants for pure skin" [3] - The company has established a robust research and development network, collaborating with the Kunming Institute of Botany since 2014, and has created a global R&D network with five bases [3] - Plant Doctor has developed a core ingredient, "Dendrobium oligosaccharides," through extensive research on high-altitude plants, which has led to market success for its flagship product line [3] Group 2: Business Model - The company focuses on a single-brand chain model, maintaining over 4,200 stores globally, which enhances brand experience and customer trust [4] - This model creates significant channel control and operational efficiencies, supported by a large network that provides valuable consumer data for product development [4] - Plant Doctor has been recognized as a leading single-brand skincare store by Euromonitor International for three consecutive years, validating the effectiveness of its business model [4] Group 3: Market Context - The cosmetics industry is moving away from rapid expansion driven by traffic and price competitiveness, with increasing pressure from homogenization and profit margins [5] - Investors and consumers are now favoring brands with clear differentiation, solid technological foundations, and sustainable profit models [5] Group 4: IPO and Future Prospects - The funds raised from the IPO will be used to enhance R&D and upgrade the global store network, reinforcing the company's competitive advantages [6] - The successful expansion into markets like Japan and Thailand demonstrates the cross-cultural appeal of its "high-altitude plant" positioning and single-brand model [6] - The journey of Plant Doctor's IPO signifies a broader trend in the Chinese cosmetics industry towards high-quality development, emphasizing brand value and operational focus [6]

Core Viewpoint - The IPO review status of Beijing Plant Doctor Cosmetics Co., Ltd. has been updated to "inquired," marking a critical stage in its journey to list on the Shenzhen Stock Exchange, representing a significant leap for a Chinese brand rooted in technology and culture to go global [1] Group 1: Brand Philosophy and Strategy - The brand's philosophy is deeply influenced by the wisdom of the Naxi ethnic group's herbal medicine, emphasizing the use of natural plant resources for skincare [3] - Plant Doctor has established a differentiated strategy by combining traditional high-altitude plant resources with modern skincare technology, creating a unique path for "Chinese brand, Chinese ingredients" [3] - The brand has successfully built a strong image of being natural, safe, and effective in the minds of global consumers, laying a solid foundation for market expansion [3] Group 2: Research and Development - The company has established the "Chinese Academy of Sciences Kunming Plant Research Institute Plant Doctor R&D Center," which serves as the cornerstone of its research capabilities [3] - Plant Doctor has developed a global R&D network with a structure of "one center, five bases," covering various locations including Beijing, Kunming, Shunde, Wuxi, and Tokyo, ensuring a complete closed-loop from basic research to industrial application [3] - The innovative transformation of large molecular Dendrobium polysaccharides into more absorbable Dendrobium oligosaccharides exemplifies the company's strong R&D capabilities, contributing to the success of its flagship product series with annual sales exceeding 5.8 billion yuan [5][6] Group 3: Market Presence and Sales Channels - Plant Doctor has adopted a unique channel model that deeply integrates products and services, focusing on offline chain operations rather than relying solely on online traffic [6] - As of June 2025, the company has over 4,200 single-brand stores globally, serving more than 30 million members across multiple countries and regions [6] - The brand has been recognized as a leader in the beauty and body care industry in China for three consecutive years and has received certification as a "global leader in single-brand skincare specialty stores" from Euromonitor International since 2023 [6] Group 4: Global Expansion and Corporate Responsibility - The company has made steady progress in its global expansion, with successful entries into markets such as Japan, Singapore, and Thailand, showcasing its vision of making the world love Chinese cosmetics [8] - Plant Doctor adheres to the philosophy of respecting nature, valuing science, and giving back to society, aligning its actions with the goals of the United Nations Development Programme (UNDP) [8] - The funds raised from the IPO will be used to enhance R&D innovation, upgrade brand image, and expand global marketing channels, positioning the company as a cultural ambassador and a responsible enterprise [8]

Core Insights - The Chinese beauty industry is undergoing a significant transformation driven by consumer upgrades and cultural confidence, with local brands focusing on cultural empowerment and technological innovation to build core competitiveness [1][3] - The IPO of Plant Doctor represents a crucial milestone for the brand and serves as a model for the feasibility of "cultural capitalization" in the beauty sector, providing a new financial perspective and industry reference for the high-quality development of domestic beauty brands [1][4] Industry Development - The cultural empowerment of domestic beauty brands has evolved from superficial symbol integration to a systematic approach that spans research, production, and marketing [1] - According to iResearch, 72% of Generation Z consumers consider brand cultural connotation when choosing beauty products, and 68% are willing to pay a premium for "cultural recognition," pushing brands to delve deeper into local culture [1][2] Plant Doctor's Strategy - Plant Doctor has transformed cultural resources, such as traditional skincare wisdom from "Compendium of Materia Medica" and local skincare secrets from Yunnan, into core inspirations for product development [2] - The establishment of the "Chinese Academy of Sciences Kunming Plant Research Institute Plant Doctor R&D Center" has led to over 200 research projects, validating the skincare efficacy of local plant ingredients scientifically [2] - The annual sales of the Dendrobium series have exceeded 1 billion yuan, showcasing the successful integration of cultural core, modern technology transformation, and market emotional resonance [2] Capitalization Process - The strategic significance of Plant Doctor's IPO extends beyond its own development, addressing the slow capitalization process in the beauty industry, which is characterized by light assets and high margins [3] - Plant Doctor's unique highland plant culture creates a differentiated advantage in market competition, allowing it to maintain a gross margin above 60% and ensuring sustainable profitability [3] - The IPO is expected to set a benchmark for the cultural empowerment track of domestic beauty brands, with a valuation potentially exceeding 10 billion yuan [3] Market Outlook - The ongoing recovery of the national economy and increasing consumer confidence provide a favorable market environment for the capitalization of the beauty industry [4] - The Chinese beauty sector is projected to increase its global market share to over 15% by 2025, breaking the monopoly of international brands in the high-end market [4] - Plant Doctor aims to leverage its IPO as a new starting point to integrate global R&D resources and channel networks, promoting highland plant culture and Eastern skincare wisdom worldwide [4]

Core Insights - The IPO of Plant Doctor is seen as a significant event marking the transition of the domestic beauty industry from a focus on traffic to value competition [1][8] - The integration of cultural empowerment and scientific research is becoming a core competitive advantage in the beauty industry [3][6] Financial Performance - Plant Doctor's revenue projections for 2022-2024 are 3.26 billion, 3.58 billion, and 3.85 billion yuan, with a compound annual growth rate (CAGR) of 8.9% [5] - The net profit attributable to the parent company for the same period is projected to be 410 million, 480 million, and 590 million yuan, with a CAGR of 24%, significantly exceeding the industry average [5] - The company's debt-to-asset ratio is expected to decrease from 42% in 2022 to 31% in 2024, indicating strong financial health [5] Strategic Initiatives - The IPO aims to raise 999.8 million yuan, with allocations of 520 million for marketing and brand building, 310 million for upgrading the research center, and 168 million for production base renovation [5] - The establishment of a 20-year strategic partnership with the Kunming Institute of Botany to create a research center demonstrates a commitment to cultural and scientific integration [3][6] Market Positioning - Plant Doctor has obtained 212 patents, including 48 invention patents, enhancing its technological barriers and product premium capabilities [6] - The brand's recognition and customer loyalty are bolstered by its certification as the top global retail brand in the iron skin orchid skincare category by Euromonitor [6] Industry Implications - The progress of Plant Doctor's IPO signifies a new phase of "value pricing" in the domestic beauty industry, moving away from reliance on traffic [8] - As brands like Plant Doctor continue to explore cultural and scientific integration, the domestic beauty sector is expected to gain a stronger presence on the global stage [8]